FOR YOUR PATIENTS
WITH UPPER GI CANCERS

BRING MORE LIFE
TO THE TABLE

Unprecedented OS in patients with 1L ESCC and PD-L1 scores ≥1%¹

Proven OS in patients with 1L GC/GEJC and PD-L1 scores ≥1%¹

Well-characterized safety profile¹

1L, first line; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; GEJC, gastroesophageal junction cancer; GI, gastrointestinal; OS, overall survival.

References: 1. TEVIMBRA. Prescribing Information. BeOne Medicines USA, Inc.; 2025. 2. Keytruda. Prescribing Information. Merck & Co. Inc.; 2025. 3. Opdivo. Prescribing Information. Bristol-Myers Squibb Company; 2025.

FOR YOUR PATIENTS
WITH UPPER GI CANCERS

BRING MORE LIFE
TO THE TABLE

Unprecedented OS in patients with 1L ESCC and PD-L1 scores ≥1%¹

Proven OS in patients with 1L GC/GEJC and PD-L1 scores ≥1%¹

Well-characterized safety profile¹

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

INDICATIONS

FOR YOUR PATIENTS WITH UPPER GI CANCERS

BRING MORE LIFE TO THE TABLE

Unprecedented OS in patients with 1L ESCC and PD-L1 scores ≥1%1

Proven OS in patients with 1L GC/GEJC and PD-L1 scores ≥1%1

Well-characterized safety profile1

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

INDICATIONS

You are being redirected to myBeOneSupport.com

FOR YOUR PATIENTS
WITH UPPER GI CANCERS

BRING MORE LIFE
TO THE TABLE

Unprecedented OS in patients with 1L ESCC and PD-L1 scores ≥1%¹

Proven OS in patients with 1L GC/GEJC and PD-L1 scores ≥1%¹

Well-characterized safety profile¹